Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback